Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Birinapant and IMRRT for Locoregionally Recurrent HNSCC
NCT03803774Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2019
- Primary completion
- Nov 2023
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of birinapant in head and neck squamous cell carcinoma (HNSCC), sponsored by National Cancer Institute. Primary endpoints: Dose-limiting Toxicities at 42 days and Maximum Tolerated Dose at 42 days. Started Sep 2019; status: active, not recruiting.
02
Drugs
birinapant
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03803774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03803774.